Relationship of serum imatinib trough level and response in CML patients: Long term follow-up

Abstract One hundred and three patients with Philadelphia chromosome or BCR-ABL positive chronic myeloid leukemia (CML) in chronic phase who were on oral imatinib were included in this study. The study aimed to assess the relationship between imatinib trough serum levels and clinical outcome (as det...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2010-12, Vol.34 (12), p.1573-1575
Main Authors: Awidi, Abdalla, Ayed, Ayed O, Bsoul, Nazzal, Magablah, Ahmad, Mefleh, Razan, Dweiri, Mohammad, Ramahi, Mohammad, Arafat, Eyad, Bishtawi, Mohammad, Marie, Lena
Format: Article
Language:English
Subjects:
Abl protein
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - pharmacokinetics
Benzamides
Child
CML
Female
Follow-Up Studies
Hematology, Oncology and Palliative Medicine
Humans
Imatinib
Imatinib Mesylate
Jordan
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality
Male
Middle Aged
Molecular response
Piperazines - administration & dosage
Piperazines - pharmacokinetics
Pyrimidines - administration & dosage
Pyrimidines - pharmacokinetics
ROC analysis
ROC Curve
Serum levels
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract One hundred and three patients with Philadelphia chromosome or BCR-ABL positive chronic myeloid leukemia (CML) in chronic phase who were on oral imatinib were included in this study. The study aimed to assess the relationship between imatinib trough serum levels and clinical outcome (as determined by molecular response) in Jordanian CML patients who have been on imatinib therapy for at least 12 months. The mean trough imatinib serum level in the group with complete molecular response (CMR) was 2891 ± 856 ng/ml, the group with major molecular response (MMR) was 2337 ± 434 ng/ml, the group with complete cytogenetic response (CCyR) was 1817 ± 563 ng/ml, and the group without CCyR was 1723 ± 673 ng/ml. A receiver operating characteristic (ROC) curve was constructed after dividing patient sample into two groups, those with MMR or better and those without MMR, in order to estimate a threshold for imatinib level that correlates with a favorable response (the former group), and analysis yielded a value of 2158 ng/ml.
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2010.07.014